{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-119514","form_type":"8-K","ticker":null,"cik":"0001697532","company_name":"Applied Therapeutics, Inc.","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.087877+00:00","generated_at":"2026-06-08T00:11:43.136070+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Applied Therapeutics appoints Les Funtleyder as CFO effective Nov 20, 2023","bullets":["Funtleyder receives $525k base salary, 40% target bonus, and 300,000 RSUs vesting over 2 years.","Catherine Thorpe ceases as interim principal financial officer; remains Chief Accounting Officer.","Severance includes 3 months base salary, 3 months COBRA, prorated bonus, and full equity vesting upon qualifying termination.","Good reason for resignation defined as >10% salary cut, material duty reduction, or relocation >50 miles.","Employment at-will; cause defined as felony, fraud, material breach of duties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-119514","json":"https://secwatch.observer/filing/0001104659-23-119514.json","markdown":"https://secwatch.observer/filing/0001104659-23-119514.md","text":"https://secwatch.observer/filing/0001104659-23-119514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697532/000110465923119514/0001104659-23-119514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697532/000110465923119514/tm2331016d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:11:43.136070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0ddb99560","claim":"Les Funtleyder was appointed as Chief Financial Officer at Applied Therapeutics, Inc..","evidence_excerpt":"appointed Les Funtleyder as Chief Financial Officer and principal financial officer of the Company, effective as of November 20, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697532/000110465923119514/0001104659-23-119514-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}